ABSTRACT Advanced molecular biology techniques developed during the past few decades have allowed the industry to exploit and commercialize the natural defense mechanisms that antibodies provide. This review discusses the latest advances in antibody-engineering technologies to enhance clinical efficacy and outcomes. For the constant regions, the choice of the antibody class and isotype has to be made carefully to suit the therapeutic applications. Engineering of the Fc region, either by direct targeted mutagenesis or by modifying the nature of its N-glycan, has played an important role in recent years in increasing half-life or controlling effector functions. The variable regions of the antibody are responsible for binding affinity and exquisite specificity to the target molecule, which together with the Fc determine the drug's efficacy and influence the drug dose required to obtain the desired effectiveness. A key requirement during antibody development is therefore to affinity mature the variable regions when necessary, so that they bind the therapeutic target with sufficiently high affinity to guarantee effective occupancy over prolonged periods. If the antibody was obtained from a non-human source, such as rodents, a humanization process has to be applied to minimize immunogenicity while maintaining the desired binding affinity and selectivity. Finally, we discuss the next next-generation antibodies, such as antibody-drug conjugates, bispecific antibodies, and immunocytokines, which are being developed to meet future challenges.
Monoclonal antibodies are enjoying outstanding commercial success, with 4 of the top 10 best-selling drugs. Although most of the preclinical and clinical experiences with therapeutic antibodies have been gained from the treatment of cancer and inflammatory diseases, effective therapy is not limited to these indications. For example, palivizumab (Synagis) has been approved for the prophylactic treatment for respiratory syncytial virus (RSV) infections and remains the only therapeutic antibody for the treatment of infectious diseases to date.
In this article, we review the latest advances in antibody-engineering technologies to make an antibody clinically and commercially successful. We discuss the rationale behind the choice of immunoglobulin isotype and the protein engineering of the constant regions. This is followed by a review of the humanization strategy to minimize immunogenicity and the recent approaches to affinity mature the antigen binding of the antibody. Finally, we have an overview of the next-generation antibodies, such as antibody-drug conjugates, bispecific antibodies, and immunocytokines, which are being developed to meet future challenges.
THE CONSTANT REGIONS: PROTEIN AND GLYCOENGINEERING OF THE FC
The Fc portion of the antibody, which determines its effector functions and is responsible for its pharmacokinetic properties, has to be carefully chosen to suit its therapeutic applications. To date, all of the approved therapeutic antibodies are of the immunoglobulin G (IgG) isotype, because IgGs are the predominant serum immunoglobulins and are readily manufacturable as biotherapeutics. Furthermore, IgG binds the Fcγ receptors (FcγRs) on immune cells to elicit various effector functions and is the only isotype that binds the protective neonatal Fc receptor FcRn, which gives typical IgGs (IgG1, -2, and -4) their long serum half-lives of about 21 days in humans.
Most of the knowledge gained on antibody therapy is from the treatment of cancer and autoimmune disorders using IgG1, the preferred IgG subclass because its potent effector functions are expected to contribute to the mechanism of action of the antibody. For infectious diseases, the only therapeutic antibody approved to date is palivizumab, also an IgG1, for the prophylactic treatment for RSV. The potent antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) of IgG1 that are desirable for eradicating cancer or autoimmune disease-causing cells, however, may not be ideal for the treatment of certain infectious diseases. In cancer therapy, the major cell types mediating ADCC are NK cells and macrophages, which also eradicate tumor cells by antibody-dependent cellular phagocytosis (ADCP). To maximize cellular cytotoxicity, optimal engagement of the activating receptor FcγRIII on NK cells and macrophage is important. On the other hand, polymorphonuclear (PMN) cells, which are about 10 times more abundant than monocytes and NK cells, constitute the first line of defense against bacteria, and FcγRIIA, the most widely expressed FcγR, is the central initiator of IgG-mediated phagocytosis by human PMN (1) . Therefore, a different strategy for engineering antibodies against infectious agents may be needed. Such a strategy should consider the choice of Ig isotypes and subclasses best suited for the disease, the glycosylation pattern to facilitate the desired mode of action, and the optimal pharmacokinetic and pharmacodynamic properties. These considerations will in turn determine the expression system, host cell lines, and production method.
Choice of Ig Isotypes and Subclasses

IgA as a potential isotype for therapeutic antibodies against infectious diseases
The majority of the antibodies approved for the treatment of cancer and autoimmune disorders are of the IgG1 subclass. Although isotypes other than IgG have not been successfully developed, IgA presents itself as a logical candidate against infectious diseases because IgAs in nature provide the principal defense against pathogens, in the first line, as IgA dimers against invasion by preventing the attachment of microbes or toxins to the mucosal lining, and, in the second line, as IgA monomers in circulation to neutralize pathogens that have breached the mucosal barrier. Furthermore, IgA represents the most abundantly produced antibody and is the second most prevalent isotype in the blood behind IgG.
IgA has two subclasses, IgA1 and IgA2. IgA1 with an extended hinge region may offer higher avidity antigen binding with distantly spaced antigens, but it is more vulnerable to proteolysis by enzymes from pathogenic bacteria (2) . IgA, especially the IgA2 isoform, has been shown to be superior to IgG1 in recruiting human PMN as effector cells to mediate ADCC (3) . In addition, ADCP by human peripheral blood neutrophils is more effectively mediated by IgA than by IgG (4) .
The IgA dimer format may be preferable in certain disease settings. However, the development of an IgA dimer is more challenging than that of a monomer. Toward that end, a recombinant dimeric IgA against epidermal growth factor receptor (EGFR) was produced and shown to mediate effective tumor cell killing. Importantly, the dimeric IgA, but not the monomeric IgA or IgG, was directionally transported by the polymeric Ig receptor through an epithelial cell monolayer in vitro (5) . This has important implications for the IgA dimer as a potential anti-infectious agent at the mucosa.
IgG and its subclasses IgG1
The human IgG1 subclass was chosen almost a priori for therapeutic antibodies. Besides being the one that is most abundant in circulation, it has potent ADCC and CDC activities, and also the most desirable chemical, manufacturing, and control (CMC) properties as a biotherapeutic, e.g., it does not have the problems that IgG2 and IgG4 have (see below). Most of the experience with therapeutic IgG1 antibodies has been for the treatment of cancer, where the importance of CDC to the mechanism of action is controversial. Based on studies in complement-deficient mice, it has been shown that the contribution of the complement pathway to proinflammatory responses initiated by IgG is minor (6). However, complement plays an important role in the phagocytosis of opsonized bacteria mediated by the complement receptors (7) . Therefore, we need to take a critical look to engineer the most effective human isotype to provide protection against infectious agents because of the different biology involved.
IgG1 binds all three classes of FcγR. Normally, FcγRI is saturated with serum IgG, which explains why this high-affinity FcγR may play only a minor role in IgGmediated cellular responses such as ADCC and ADCP (6) . The binding of IgG1 to the inhibitory FcγRIIB and the glycosylphosphatidylinositol-anchored FcγRIIIB, which does not signal, may render IgG1 suboptimal in triggering effector functions by PMN (4) . Surprisingly, in a mouse study designed to compare the efficacies of human IgG subclasses with identical V regions against a yeast infection (Cryptococcus neoformans, which causes meningitis in AIDS patients), IgG2 and IgG4, which have few ADCC/ADCP and CDC activities, respectively, protected the mice, whereas for the effector functions competent counterparts, IgG3 had no effect and IgG1 actually potentiated the infection (8) . This unexpected result was explained by the observation that phagocytosed yeast was not killed to a significant extent, and the macrophages can possibly act as a Trojan horse for its survival and dissemination (9) . Interestingly, studies in complement-deficient mice suggested that complement may also play a role in the antibody-mediated enhancement of cryptococcal infection (10) .
IgG2
Although IgG2 is often considered as the effector-silent isotype in cancer treatment, it should be noted that the principal effector cells in the human peripheral blood mononuclear cell used in the classical in vitro ADCC assay are NK cells, which express only FcγRIII. In this assay, IgG1 and IgG3 are the most potent, while IgG2 and IgG4 have no detectable activity.
However, it has been reported that IgG2 can trigger ADCC by neutrophils mediated by FcγRIIA (11) . This finding may explain the discrepancy between the lack of in vitro ADCC using NK cells, and yet readily detectable cytolytic activities of anti-CD8 IgG2 and IgG4 in mice (12) , and, more importantly, the cytolytic activity of alemtuzumab (Campath) IgG4 in humans (13, 14) . In addition, although complement plays a role in the phagocytosis of opsonized bacteria mediated by the complement receptors, IgG2 engagement of FcRIIA alone on phagocytic cells can lead to phagocytosis of opsonized bacteria (7) .
IgG2 exhibits disulfide structural heterogeneity, resulting in at least three isoforms which differ by the disulfide connectivity at the hinge region (15) . This can be more than a CMC issue on the homogeneity of the product, since some of the isoforms have been shown to affect binding affinity (16) . IgG2 hinge region homogeneity with uniform disulfide bonds can be readily achieved by the use of a modified IgG1 hinge (17) .
IgG3
IgG3 has an extended hinge region that imparts greater segmental flexibility and motion, resulting in a larger angle and longer distance between the two binding sites, to attain bivalent binding (18) . It is for this reason that the IgG3 subclass was chosen for the development of a class of antibody cytokine fusion proteins (19) . This extra spacing and flexibility provided by the IgG3 hinge may be particularly relevant for antiviral antibodies, because viruses such as the human immunodeficiency virus (HIV) have envelope spikes that are few and far between (20) . Such spacing between epitopes is a strategy HIV has evolved to avoid bivalent binding to thwart neutralization by antibodies. For development as a biotherapeutic, IgG3 suffers from the fact that it has a relatively short serum half-life of about 7 days in humans.
IgG4
The IgG4 subclass is usually chosen for its complete lack of CDC, low ADCC (despite its high binding affinity for FcγRI [21] ), and anti-inflammatory activity (22) . The hinge region of the IgG4 H chain has two cysteine residues that can form either an intrachain disulfide bond or two interchain disulfide bonds with its partner H chain, and this accounts for the presence of about 50% of half-molecules (HL, a light chain bound to one heavy chain) when IgG4 is analyzed by sodium dodecyl sulfate-gel electrophoresis under non-reducing conditions. This heterogeneity is more than a CMC issue because recently it has been shown that therapeutic IgG4 antibodies can engage in Fab-arm exchange with endogenous human IgG4 in vivo (23) , resulting in the functional monovalency of IgG4, with the loss of binding avidity and cross-linking effects. It is noteworthy that of the two approved therapeutic IgG4 antibodies, only gemtuzumab contains a hinge modification, whereas natalizumab does not (24) . Indeed, natalizumab showed significant levels of Fab-arm exchange in 15 of 16 patients, as early as 1 h after infusion (23) . Therefore, therapeutic IgG4 antibodies should be designed to prevent the Fab-arm exchange by introducing the S228P mutation to stabilize the hinge region, and, more importantly, the R409 K mutation to stabilize the CH3 region (25) . On the other hand, this Fab-arm exchange property of IgG4 can be exploited to generate recombinant bispecific therapeutic antibody, such as the Duobody of Genmab (Utrecht, The Netherlands).
Fc Glycosylation and Effector Functions
The N-glycan in the Fc is essential for the engagement of the FcγRs (but not FcRn) and hence important for effector functions. Therefore, antibodies whose effector functions are important for their mechanisms of action ASMscience.org/MicrobiolSpectrumhave to be produced in mammalian cells, or, more recently, in glycoengineered yeast (26) . Importantly, the nature of the N-glycan chain, such as the presence of the bisecting N-acetylglucosamine (GlcNAc), fucose, and terminal sialic acids, modulates the activation of the FcγRs and immune cells.
Bisecting GlcNAc and fucosylation impact ADCC
It was recognized early on that the glycosylation pattern and biological activity of alemtuzumab expressed in different cell lines varied. The alemtuzumab produced from rat myeloma cells had a bisecting GlcNAc and a low extent of fucosylation, and it showed the highest ADCC (27) . Although antibodies produced in β(1,4)-Nacetylglucosaminyltransferase III (GnTIII) transfected Chinese hamster ovary (CHO) cells had improved ADCC because of the addition of the bisecting GlcNAc (28) , it was recognized later that the absence of fucose was dominant over bisecting GlcNAc in enhancing the ADCC. Indeed, the enhancement effect of bisecting GlcNAc was only observed in highly fucosylated IgG1, which has low ADCC activity (29) .
Since ADCC was considered as an important mechanism of action for a number of therapeutic antibodies, and NK cells, the effector cells used in standard ADCC assays in vitro, express only FcγRIIIA, technology to improve FcγRIIIA binding of antibodies received a lot of attention. Furthermore, increased FcγRIIIA binding may also enhance antigen uptake by FcγRIIIA-expressing dendritic cells and macrophages, thus potentiating the adaptive immune surveillance.
The importance of ADCC to antitumor activity was supported by clinical data, which showed that response to antibody therapy was positively correlated to the binding affinity of FcγRIIIA to IgG1. For rituximab (Rituxan) in the treatment of non-Hodgkin's lymphoma, Waldenströms macroglobulinemia, and follicular lymphoma, FcγRIIIA polymorphism was found to be a good predictor of clinical outcome, with patients expressing the 158V variant, which has a higher binding affinity for IgG1, responding better than patients expressing the 158F variant (30, 31) . Similar positive correlation was also reported for trastuzumab (Herceptin) in the treatment of metastatic breast cancer (32) , and for Erbitux in the treatment of metastatic colorectal cancer (33) . There is also direct evidence that increasing the binding affinity of an antibody for FcγRIIIA translates to improved efficacy in the clinic. Anti-RhD monoclonal antibodies (mAbs) produced in YB2/0 cells, which have low fucose levels, demonstrated superior clearance of RhD-positive red blood cells, relative to monoclonal antibodies produced in other producer lines (34) .
It should be noted that, while antibodies with low fucose levels have enhanced ADCC mediated by NK cells, they were found to be less potent in inducing ADCC mediated by activated PMN, in comparison with antibodies with high fucose levels. PMN express FcγRIIA, and, instead of FcγRIIIA, the glycosylphosphatidylinositol anchored FcγRIIIB, which does not have the signaling ability to trigger effector functions by PMN. Since fucosylation levels on antibodies are not known to affect binding to FcγRIIA, it is possible that the higheraffinity binding of antibodies with low fucose levels to FcγRIIIB acts as a decoy mechanism, resulting in less binding to FcγRIIA, the receptor responsible for activating the PMN-mediated ADCC (35) . This shows that the impact of Fc glycosylation on ADCC is critically dependent on the recruited effector cell type, an important point to consider when designing antibodies for the treatment of infectious diseases.
Manipulating effector functions and pharmacokinetic properties
In addition to the aforementioned GnTIII-transfected CHO cells by Roche Glycart (Schlieren, Switzerland) to produce antibodies with bisecting GlcNAc, an α-1,6-fucosyltransferase (FUT8) knockout CHO cell line was developed by Kyowa Hakko Kogyo (Tokyo, Japan) to produce nonfucosylated antibodies (36) . Furthermore, glyco-optimized and fully human glycosylated antibodies can be produced from glycoengineered mammalian cells (Glycotope, Berlin, Germany) or yeast (GlycoFi Merck, Lebanon, New Hampshire) (25) .
Instead of glycoengineering, Fc mutations can be introduced to optimize binding to specific FcγRs, such as increased binding to activating FcγRs and decreased binding to the inhibitory FcγRIIB, thereby improving the so-called A/I ratio, to enhance ADCC and ADCP (37, 38, 39) . On the other hand, for therapeutic applications where effector functions are undesirable, mutations to abrogate ADCC and CDC are well described in the literature. One common strategy is to incorporate natural motifs from IgG2 and IgG4 to decrease binding to FcγRs and complement, respectively, while keeping potential immunogenicity of the changes to a minimum. For example, Armour et al. (40) replaced residues 233 to 236 in the lower hinge region of IgG1 responsible for FcγR binding with the corresponding residues from IgG2, and introduced IgG4 residues at position 327, 330, and 331 to abolish binding to C1q. Similarly, the "effector silent" IgG2/G4 composite antibody of Mueller et al (41) and the IgG2m4 of An et al. (42) were all based on incorporating the nonbinding motifs of IgG2 and IgG4. However, as mentioned earlier, incorporating natural motifs from IgG2 and IgG4 does not necessarily mean complete elimination of binding. In fact, it was recognized that IgG2 and IgG4 can lead to unwanted side effects, presumably caused by residual interactions with FcγRIIA (H131) and FcγRI (43) . It should be pointed out that complete removal of N-glycan greatly impaired binding to cellular FcγRs and C1q (44) , without affecting the interaction with FcRn (37, 45) . Therefore, an aglycosylated form of IgG2 may offer the best approach to "effector silent" antibodies (46) . This is supported by the alemtuzumab study, which showed that the IgG4 subclass, despite the lack of ADCC in vitro, had cytolytic activities in humans, whereas the aglycosylated form had neither in vitro nor in vivo cytolytic activities (13, 14) .
In addition to optimizing the binding to FcγRs selectively, Fc mutations were also introduced to increase binding to FcRn at acidic pH, but not at neutral pH, thereby enhancing the recycling of IgG from the endosomes back to the circulation. The affinities of therapeutic IgGs and Fc-containing proteins for FcRn at pH 6.0 were shown to be closely correlated with their serum half-lives from clinical studies (47) . One wellcharacterized Fc mutant with enhanced binding to FcRn has the triple mutations YTE (M252Y/S254T/T256E) introduced into the Fc portion of an anti-RSV monoclonal antibody, resulting in 10-fold increase in binding to human and monkey FcRn at pH 6.0 but not pH 7.4. This translates to a fourfold improvement in serum halflife in monkeys (48) . With human FcRn knock-in mice being commercially available now, serum half-life of therapeutic antibody candidates can be compared conveniently in this surrogate host (49) .
It should be noted that FcRn, while primarily known as a neonatal receptor and a protective receptor for IgG, can also be exploited to mediate immune functions against infections. Its expression is not restricted to endothelial and epithelial cells, but also found in human monocytes and dendritic cells. FcRn on these immune cells can translocate to nascent phagosomes, thereby facilitating IgG-mediated bacterial phagocytosis (50) .
Fc sialylation
High levels of sialylation of the Fc glycans in IgGs are associated with reduced binding to FcγRIIIA on NK cells, resulting in lower ADCC both in vitro (51) and in an in vivo model of immune thrombocytopenia (52) . However, it is not clear whether this is entirely due to lower-affinity binding to FcγRIIIA specifically, or also partly due to lower binding to cell surface antigens in general, because many cell surface antigens and receptors have terminal sialic acids (51) . What is certain is that the effect of sialylation on FcγR binding was independent of the 2,3-and 2,6-linkage of the sialic acid to the penultimate galactose on the complex biantennary N-linked glycan (52) .
The 2,6-linkage, however, is definitely responsible for the anti-inflammatory activity of intravenous immunoglobulin treatment, which has been widely used to treat autoimmune diseases such as immune thrombocytopenia, rheumatoid arthritis, and systemic lupus erythematosus. Interestingly, the receptor responsible for the binding of 2,6-sialylated IgG is not one of the canonical FcγRs, but a C-type lectin receptor DC-SIGN on dendritic cells, resulting in the secretion of soluble antiinflammatory mediators that increase surface expression of FcγRIIB on macrophages found at the site of inflammation (53) . Subsequent cross-linking of FcγRIIB and activating FcγRs on the macrophage by the autoantibody in the immunocomplex results in inhibition of macrophage activation, which accounts for the antiinflammatory activity of intravenous immunoglobulin. Therefore, enhancing the 2,6-linkage sialylation of IgG may be an effective way of increasing anti-inflammatory activity of therapeutic antibodies, e.g., in the treatment of infectious diseases where controlling inflammation is of paramount importance. It is interesting to note that, despite that only 5% of the total serum IgG is fully sialylated, innate IgGs are generally anti-inflammatory in the steady state; the extent of sialylation is reduced in the course of an antigen-specific immune response so that the IgGs become more proinflammatory (54) .
Aglycosylated Fc
Production of full-length antibodies has been done exclusively in eukaryotic cells because of their complex tetrameric structure and the posttranslational glycosylation critical for effector functions. The demonstration that heavy and light chains can be efficiently secreted and assembled in the Escherichia coli periplasm paved the way to an inexpensive method for the manufacture of therapeutic antibodies, especially for treatment in which effector functions are not desirable (55) .
Aglycosylated antibodies retain binding to FcRn (37) and have been shown to have normal pharmacokinetic profiles in the clinic (56) . If effector functions are desirable, point mutations can be readily introduced to restore FcγR and complement binding, and, better still, selectively engage certain FcγRs to achieve a more favorable A/I ratio (56, 57, 58) , especially for the treatment of certain infectious diseases in which enhancing phagocytosis is important.
HUMANIZATION
The key factor to reducing the inherent immunogenicity of a product candidate is to make the therapeutic monoclonal antibody as similar as possible to naturally occurring human immunoglobulin sequences without losing the changes that result in the desired functional properties.
Humanized antibodies are antibodies from nonhuman species whose amino acid sequences have been changed to improve their similarity to antibody variants produced naturally in humans. Before rodent antibodies can be used in clinical application, it is essential to humanize them to decrease their immunogenicity and increase their activity in the human immune system. Antibody humanization comprises proven strategies for lessening the immunogenicity of well-characterized mAbs from animal sources (commonly mice) and for ameliorating their activation of the effector functions of the human immune system, thus producing clinical diagnostics and therapeutics. To overcome the immunogenicity triggered by non-human biologics, approaches such as the development of hybridomas and B-cell cloning from antibody-secreting cells from human peripheral blood and the production of human antibody repertoires in transgenic mice or on the surface of different display systems have emerged as platforms for engineering fully human therapeutic antibodies. However, because there are neither royalties nor license fees attached to the use of the hybridoma technology, the development of animal (mainly mouse) monoclonal antibodies as therapeutics remains a very attractive alternative providing that they are humanized to translate high-quality non-human antibodies to the clinic.
CDR Grafting: Standard Technology
In the past 25 years, multiple strategies for the humanization of mAbs have been reported in the literature. However, complementarity determining region (CDR) grafting onto a homologous (high-sequence homology) human antibody framework (acceptor) remains the most utilized technique for mAb humanization (59) . Strict CDR grafting usually results in significant to complete loss of antigen recognition by the acceptor antibody. This problem can be resolved by backmutating critical framework sites on the acceptor to the corresponding amino acid residues in the donor sequence. These critical framework residues for back-mutation are selected from the wealth of published structural data on antibodies and/or from the homology-modeled structure of the mouse Fv sequence that reveals the framework positions important for maintaining the integrity of the Ig fold or for supporting the conformation of the CDR (canonical residues). Figure 1 describes the main decision-making points during the CDR-grafting process and their evolution over the years. CDR grafting guided by molecular modeling is a well-validated approach that has been instrumental for the development of several FDAapproved antibodies, such as Tysabri (60) and Actemra (61) . For a detailed description of the standard technology, see review by Leger and Saldanha (62).
Alternative Approaches
Veneering or resurfacing
It was proposed by Padlan (63) that murine variable domains could be veneered to reduce their antigenicity. Veneering, also known as resurfacing, is a technique whereby the exposed framework residues are replaced by amino acids found at corresponding positions in human antibody sequences. Although many antibodies have been humanized by variable domain resurfacing, to our knowledge, no clinical studies with these antibodies have been published until now.
Grafting of abbreviated CDRs containing SDRs
CDR-grafted humanized antibodies carry xenogeneic CDRs which may evoke antivariable region, including anti-idiotypic, responses. Not all the CDR residues of a murine antibody are essential for antigen binding; this rationale comes from a comprehensive analysis of the three-dimensional structures of the antibody combining site where it was suggested that only 20 to 33% of the CDR residues are critical in the antigen-antibody interaction (64) . These residues, located in the regions of high variability and most likely unique to each antibody, are designated as specificity-determining residues (SDRs). A new approach to the humanization of antibodies, therefore, was based on grafting only the SDRs of a xenogeneic antibody into the human antibody frameworks. The immunogenicity of an antibody therefore could be reduced by transplanting only those parts of the CDRs that contain the SDRs. The "abbreviated" CDRs have been defined (65) as the boundaries of the potential SDRs in various antigen combining sites.
Superhumanization
This humanization strategy is based on structural homologies between mouse and human CDRs and essentially ignores the frameworks. The first step of this CDR-grafting method is to identify human germ line V genes that in combination have the same canonical structure class as the mouse antibody to be humanized. Within that matching subset, typically a half-dozen genes from 44 functional VH or 41 functional VL genes in the human genome, H and L chain gene segments are picked whose CDRs have the best residue-to-residue homology to the mouse antibody. In the selected sequences, the remaining nonhomologous CDR residues are simply converted to the mouse antibody sequence. mAbs constructed by this strategy retain the ability to bind antigen, and, because they are CDR grafted in a way that minimizes deviation from human sequences, such Abs are called "superhumanized" (66) .
Because the choice of the human frameworks is driven by the sequence and structure of the CDRs, this strategy has the potential to generate humanized antibodies that retain good binding to their cognate antigen. However, the general applicability of such a framework-ignoring strategy is uncertain since (i) favorable conformation(s) of a given CDR can be uniquely dependent on some specific source framework residues (canonical residues), and (ii) particular source framework residues may, in some cases, actively participate in direct interactions with the antigen as has been observed in certain antigen/ antibody complexes.
Human string content optimization
Recently, Lazar et al. (67) have introduced a new method of humanization based on a novel and immunologically relevant metric of antibody humanness, termed human string content, that quantifies a sequence at the level of potential major histocompatibility complex/T-cell epitopes. Human identity is defined as the number of total "human 9-mers," which is an exact count of 9-mer stretches in the Fv that perfectly match any one of the corresponding stretches of nine amino acids in their set of functional human germ line sequences. Human 9-mer content is used as a measure of T-cell tolerance (i.e., if a stretch of nine consecutive amino acids matches one of the human germ line segments, it is more likely that T cells will not recognize it because of developmental tolerance for the original human 9-mer). This approach utilizes the homology present in human germ line sequences to make murineto-human substitutions that increase the human sequence content of the Fv.
Framework shuffling and human framework adaptation
Dall'Acqua et al. (68) describes a new humanization approach called "framework shuffling" that does not require any rational design or structural information and for which there is no need to design backmutations. In this method, a given non-human monoclonal antibody is humanized by synthesizing a combinatorial library comprising its six CDRs fused in frame to a pool of mixed and matched human germ line frameworks. These human frameworks encompassed all known heavy-and light-chain human germ line genes. Libraries were cloned into an M13-based phage expression vector. The primary screen consists of a single-point enzymelinked immunosorbent assay using periplasmic extracts prepared from individual recombinant M13 clones. Recently, an alternative to the FR shuffling, human framework selection, was described by Fransson et al. (69) as the first step of a new humanization method called human framework adaptation. In this method, the human germ line genes are selected based on sequence and structural considerations. This is followed by a second step of SDR optimization.
Combinatorial library approaches Guided selection
An alternative method, guided selection, has been developed to convert murine antibodies into completely human antibodies with similar binding characteristics. This methodology was originally developed by Jespers et al. (70) . In this method, mouse VH and VL domains are sequentially or in parallel replaced by human VH and VL domains, respectively, using phage selection to derive human antibodies with best affinity. A potential disadvantage of the guided selection approach is that shuffling one or both antibody chains can result in epitope drift (71) . This can however be seen as an advantage for introducing minor but essential changes in specificity such as removing cross-reactivities to unwanted antigens (72) . To maintain the epitope recognized by the source non-human antibody, CDRs can be conserved. In this alternative method, one or both nonhuman CDR3s are commonly retained since they usually play a critical role in the recognition of the antigen.
Combinatorial library strategy
Rosok et al. (73) , using a combinatorial approach and colony lift as selection method, have described a general antibody-engineering strategy that combines elements of structure-based approaches with in vitro evolution strategies to address the difficulty of maintaining antibody binding activity following humanization. More recently, also using the combinatorial approach but phage display as selection method, Rader et al. (74) 
Concluding Remarks on Humanization
There is no simple correlation between sequence humanness and immune response, as illustrated by the virtual absence of immunogenicity for the CDR-grafted humanized antibody trastuzumab and the 5 to 89% neutralizing response rate in a subset of patients, which varies depending on the disease and the therapy, to the fully human mAb adalimumab (Humira) (76) . Many factors in addition to protein sequence can affect immunogenicity, such as dose and administration parameters (route, duration, and frequencies, as well as target-specific effects), but one of the most critical factors is the biophysical properties of the final molecule (77) . These properties should be carefully monitored during the humanization process.
To conclude, we propose that a mixing and matching of techniques could be used in future protocols to take into consideration all the different aspects of humanization that we considered above with the ultimate goal of engineering fully human monoclonal antibodies. Such an attempt has recently been reported by Bernett et al. (78) . Starting from the source murine variable regions of three currently marketed mAbs targeting CD25 (daclizumab), vascular endothelial growth factor (bevacizumab), and tumor necrosis factor alpha (infliximab), they generated "fully human" antibodies. All three engineered mAbs had levels of sequence humanness comparable to other fully human mAbs and yet maintained antigen binding and in vitro activity comparable to the three marketed drugs.
AFFINITY MATURATION
The antibody leads resulting from the discovery efforts meet established criteria regarding affinity and specificity. Affinity to the target molecule defines the future monoclonal antibody drug's efficacy and influences the drug dose required to obtain the desired effectiveness. A key requirement during antibody development is therefore to engineer a molecule with sufficiently high affinity to guarantee effective occupancy over prolonged periods. On one hand, for neutralization of soluble antigens, like cytokines, or viruses, the neutralization efficiency seems to be well correlated with the binding affinity. On the other hand, the assessment of affinity goals for antibodies against membrane receptors is often challenging.
In Vivo Affinity Maturation
The affinities of antibodies obtained in vivo tend to fall within characteristic ranges constrained by biological requirements imposed during the ontogeny of B cells. Specific antigen recognition by a surface antibody on a B cell, followed by endocytosis, leads to efficient antigen presentation (79) , initiating cytokine release, B-and T-cell proliferation and differentiation, somatic hypermutation, and so on. Foote and Eisen (80, 81) argued that the residence time of an antigen complexed to a B-cell surface antibody would constrain the dissociation rate constant (k off ) selectable in vivo. The essence of their proposal was that antibody-antigen complexes with lifetimes much longer than the time necessary for uptake would all be processed equally well, hence, could not be distinguished. This idea of an intrinsic affinity ceiling for the selection of antibodies generated in vivo was supported by the result of a study by Batista and Neuberger (82) . To study how signaling and antigen presentation through B-cell receptors depend on antigen/ B-cell receptor affinity, lysozyme-specific B-cell transfectants were challenged with mutated lysozymes differing in their binding kinetics. The results of their study confirmed the predicted ceiling value for K a in the order of 10 10 M −1 (K d of 100 pM) proposed by Foote and Eisen. This, of course, does not imply that antibodies with affinities greater than 100 pM cannot be obtained; rather, there is unlikely to be actual selection in favor of mutations that take affinities beyond this value. This prediction of an in vivo affinity ceiling has been frequently challenged. Indeed, with the use of transgenic mice producing fully human antibodies, the generation of antibodies with subnanomolar affinities (less than 10 pM) has frequently been reported (83) . The existence of an in vivo generated antibody to interleukin-8 with a subpicomolar affinity (610 fM) has also been reported (84) . This confirms that, by using efficient antibody generation procedures to screen a larger proportion of the available immune repertoire in hyperimmune animals, it is possible to isolate antibodies with exceptionally high affinities well beyond the proposed affinity ceiling.
Generation of high-affinity antibody against T celldependent antigen has also been described in germinal center-associated DNA primase gene-transgenic C57BL/ 6 mice (Ganp Tg ). Recent data suggest that germinal center-associated DNA primase may serve as an essential link required to transport activation-induced cytidine deaminase (AID), whose action during transcription is necessary for somatic hypermutation (SHM) (85) , to actively transcribed immunoglobulin variable regions (86) . These Ganp Tg mice generate exceptionally high-affinity monoclonal antibodies against nitrophenylhapten, HIV-1 (V3 peptide)-epitope (87) and SARSCoV-epitope (K d > 10 −11 M) (86) . These mice develop Hodgkin-like lymphomas of non-T and non-B surface phenotype with multiple mutations at immunoglobulin variable heavy chain region genes (88) . Custom production of antibodies using these mice is offered by Trans Genic Inc.
In Vitro Mutagenesis, Display, and Selection
In vitro mutagenesis remains one of the most commonly used and widely accepted strategies for affinity maturating antibodies to the nanomolar (89), picomolar (90), or even femtomolar (91) range. In vitro antibody display technologies, such as phage, yeast, and ribosome display, have been widely utilized to increase antibody affinity. There are many options for diversifying V genes for affinity maturation, including the random introduction of mutations, for example, by error-prone PCR, CDR mutagenesis using spiked oligonucleotides and chain shuffling. These different strategies have been reviewed extensively (92, 93) . Here we are going to describe some alternative and new developments for in vitro affinity maturation of antibodies.
In vitro affinity maturation by somatic hypermutation
The genetic diversity created by the immune system is so large that, for nearly every foreign antigen, an antibody can be generated to bind it. After combinatorial rearrangement of gene segments, the antibody variable region is mutated at a rate orders of magnitude greater than the spontaneous mutation rate. This occurs when activated B cells encounter antigen and is termed immunoglobulin (Ig) SHM. AID is essential for the initiation of SHM in B cells by the deamination of cytidine residues directly in Ig genes (94) . To achieve this, AID is targeted to V-region DNA sequences, termed hotspots (e.g., WRCH) that result in mutations and amino acid substitutions, which are frequently in positions biased to modulate antigen binding (95) . Expression of AID alone has been shown to be sufficient to reproduce the salient features of SHM in both B cells (96, 97) and other mammalian cells (98) . However, these cell lines are difficult to transfect at efficiencies suitable for use with diverse libraries. Nevertheless, the potential of using SHM in vitro has been apparent since Cumbers et al. (99) were able to evolve the endogenous IgM in Ramos cells to recognize streptavidin with an apparent affinity of 11 nM after 19 rounds of fluorescence-activated cell sorting; demonstrating that hypermutating cell lines can be used for iterative maturation of antibodies in vitro (99) . More recently, Bowers et al. (100) have developed a novel approach where, by coupling in vitro SHM with mammalian display, they were able to affinity mature an antibody to human β-nerve growth factor, as full-length, glycosylated IgGs, to low pM K d .
Affinity maturation of antibody by mammalian display
Problems with protein folding, posttranslational modification, and codon usage still limit the number of improved antibodies that can be obtained by display of antibodies on the surface of microorganisms (phage, bacteria, and yeast). An ideal system would select and improve antibodies in a mammalian cell environment where they are naturally made. Ho et al. have described a system to display single-chain anti-CD22 Fv fragments on human embryonic kidney 293T cells (101) . In a proof-of-concept experiment, cells expressing a rare mutant antibody with higher affinity were enriched 240-fold by a single-pass cell sorting from a large excess of cells expressing wild-type antibody with a slightly lower affinity. Furthermore, they successfully obtained a highly enriched mutant with increased binding affinity for CD22 after a single selection of a combinatory library randomizing an intrinsic antibody hotspot. Standard transfection or electroporation methods, however, will typically introduce multiple copies of vectors into each cell. It is difficult to control the number of vectors introduced into each cell and, more importantly, the location of the integration into the host cell genome. Multiple copies of vectors and multiple integration sites in the host cell create a time-consuming process for screening and characterization. It also becomes extremely difficult to compare precisely the affinity and expression on the mammalian cell surface and isolate the desired cell clones efficiently. Zhou et al. described a novel mammalian full-length IgG display system successful in solving the critical issues of single specificity and relatively equal expression through the recombinase Flp-mediated single-copy integration. They demonstrated the application of their system in affinity maturation, identifying anti-OX40 ligand mutants of parental mAb40-L11 antibody with significantly improved neutralizing activity from a randomly mutagenized library (102) . More recently, two other mammalian cell-displayed full-length antibody display systems that could be used for affinity maturation have been described (103, 104) .
Affinity maturation by somatic mutations and computational design
Recent advances in computational technologies combined with dramatic advances in high-throughput technology have the potential to make important contributions to the development of biological therapeutic antibodies (105) . In the ideal case where high-resolution antibody structures or, preferably, antibody-antigen complex structures are available, determination of contact residues is straightforward, and this information can be applied to guide the maturation process (106) . If experimentally determined structures are not available, but the paratope has been reliably mapped, a threedimensional model of the variable domains can be constructed (107) and the residues affecting affinity can be projected onto it (108), thereby facilitating the selection of candidate positions for maturation. For review of recent progress in the field of computer-aided antibody development mainly focusing on antibody modeling, see Kuroda et al. (109) . Improvements are still needed in all of the computational approaches; for example, understanding loop flexibility is particularly important in antibody design because large conformational changes can occur upon antigen binding, and affinity maturation can modulate both the conformation and dynamics of the CDR loops.
In terms of improvements of the properties in antibodies, such as immunogenicity and solubility, sequence-based methods have shown promise in antibody engineering (110, 111) .
In Vitro Affinity Maturation without Display
The widespread use of phage and yeast display can be attributed largely to the fact that, when well implemented, very complex libraries can be screened relatively easily by panning or cell sorting, respectively. However, the "single-pot" phage display panning approach of large libraries has well-documented draw-backs with respect to selection bias toward variants that are better displayed or that allow faster growth of the expressing host cell (112, 113) . The effects are magnified over the multiple rounds of selection and amplification, so that useful candidates may be lost, if they do not also compete well in these therapeutically irrelevant selection criteria. In addition, it is impractical to generate and screen by display methods many dozens of mutagenic libraries simultaneously but individually, an approach that proved important in the present work. Finally, display methods generally have an insufficient dynamic range to allow reliable isolation of the tightest protein target binders when starting with an already tightly binding antibody. As an alternative to display methods, antibody variants can be tested in a clonal, well-based, high-throughput screening process with quantitative determination of properties to ensure selection of candidates with the best mix of desired characteristics.
Votsmeier et al. (91) describe an elegant and generic method to improve antibody affinities without phage or cell surface display. In their approach, they used clonal, quantitative, well-based high-throughput screening for selection of soluble Fab (fragment antigen binding) expression of the library variants and limited library diversification to CDRs only. In each library, two neighboring residues were fully diversified. The mutation pairs in each screening hit were deconvoluted to identify contributions from each individual residue change. In total, 33 double-NNK libraries were generated, encompassing all 62 CDR positions of adalimumab (114) . Their multistep optimization approach includes a first "mutation gathering" round of library generation and screening, followed by rounds in which the gathered mutations are recombined. They applied their approach to the affinity maturation of antitumor necrosis factor (TNF) antibody adalimumab, which binds TNF with ∼100 pM affinity, and achieved ∼500-fold affinity improvement, resulting in femtomolar binding. With similar reasoning, adalimumab was previously subjected to affinity maturation by using a single-chain variable fragment (scFv) yeast display approach including diversity generation at every CDR residue position and recombination of the beneficial mutations (115) . In comparison with Rajpal et al., the Votsmeier et al. process resulted in fewer mutations for a given affinity increase. Given the large flexibility in assay design of well-based screening, the approach described by Votsmeier et al. has clear applications to other antibody properties, such as stability, solubility, selectivity, species cross-reactivity, expression yield, receptor modulation, or cellular responses.
THE NEXT-GENERATION ANTIBODIES TO MEET FUTURE CHALLENGES
Despite mAbs having outstanding commercial success with 4 of the top 10 best-selling drugs in 2009 (116), they suffer from several shortcomings. First, the addressable target space appears to be limited, causing fierce competition. In oncology, for example, nine marketed products correspond to only six different targets (vascular endothelial growth factor, EGFR, Her2, CD20, CD33, and CD52). For autoimmune and inflammatory diseases, four TNFα-neutralizing mAbs have been marketed (infliximab, adalimumab, golimumab, and certolizumab PEGol) (117) . The number of mAb launches validating new targets is limited to only a few per year, demonstrating that new therapeutic target discovery is an elusive and costly business. Another major drawback is that mAbs have relatively low clinical efficacy and are usually not effective as monotherapy in cancer. As a consequence of their large molecular weight and complex structure, mAbs do not penetrate tissues very well and need to be administered parenterally. In addition, manufacturing of mAbs is complex and costly.
Several "Next-Generation Antibody" technologies have been developed to overcome one or more of the liabilities mentioned above. The smaller size and less complex structure of antibody fragments and alternative scaffold binders are cheaper to produce and may have better tumor penetration (118) . Antibody drug conjugates (ADCs), bispecific antibodies, and the glycoengineering of the Fc glycan mentioned above may result in antibodies with improved efficacy (119) . However, all these technologies have one thing in common: they are still nascent and it remains to be shown that the innovation translates into clinical and commercial success.
Antibody Drug Conjugates
One approach to increase the efficacy of mAbs in the treatment of cancer and virally infected cells is the antibody drug conjugates (ADC) concept (120, 121) . Because small-molecule cancer drugs often have issues with dose-limiting systemic toxicities, the concept of ADC is to use mAbs to target those compounds directly to the tumor. To this end, conjugated agents may include small-molecule drugs, toxins, radionuclides, proteins, peptides, and other classes (122) . Although two radionuclide conjugates, Zevalin and Bexxar (123) , have been marketed, neither of those molecules is a particular commercial success, and it appears that industry nowadays has regained interest for conjugation of smallmolecule drugs to antibodies (124) . The idea of using an antibody chemically linked to a cytotoxic small molecule to target a tumor is more than 25 years old, but the therapeutic index appeared to be an issue. Gemtuzumab ozogamicin (125) , a conjugate of calicheamicin to a humanized anti-CD33 mAb, was released in 2000 but subsequently withdrawn because of production and safety concerns (126) . Only recently, another ADC was launched, and some 20 are in the clinical pipeline (124) . Brentuximab vedotin, a conjugate of an auristatin derivative to an anti-CD30 antibody (127) , was developed by Seattle Genetics in collaboration with Millenium, and approved for the treatment of relapsed and refractory Hodgkin's lymphoma. Another advanced clinical candidate, T-DM1, which is a maytansinoid fusion with Roche Genentech's Trastuzumab, is currently in Phase 3 for Her2+ metastatic breast cancer (128) . T-DM1 exploits the ADC technology developed by Immunogen, Seattle Genetics' major competitor. Both types of payloads, Seattle Genetics' auristatins and Immunogen's maytansinoids, are highly potent antimitotic agents that show intrinsic activity in proliferating cells.
To achieve an optimal ADC, several parameters need to be considered. In general, it is important to utilize a highly selective antibody directed against a cell surface receptor that is overexpressed on tumor cells relative to normal tissues to avoid unwanted side effects. If the toxin is active inside the cell, such as the tubulin blockers or DNA-methylating agents, the ADC needs to be internalized by the target cell after ligand binding and the toxin released to initiate the cytotoxic activity. The chemical linker connecting the small-molecule toxin and the antibody plays a critical role for every ADC concept, and cleavable and noncleavable linkers have been described. While noncleavable linkers release the toxin by degradation of the antibody in the lysosomal pathway, release of the payload from cleavable linkers is either driven by enzymatic activity or by acidic pH in the hypoxic environment inside a tumor (129) .
On the CMC side, ADC appears to be particularly challenging (130) . Chemical conjugation of drug-linker complexes to mAbs needs to be carefully controlled to guarantee product homogeneity. Depending on the chemistry utilized, several conjugations can take place at multiple sites of a single mAb molecule, and the number of toxins added needs to be optimized and controlled. In addition, conjugation of a drug-linker complex may change the CMC properties of the ADC relative to the parental antibody requiring more complex production processes and analytics. In summary, developing an ADC is challenging, and, thus, it is no surprise that these medicines come along with a steep price tag. In 2011, Seattle Genetics announced that the treatment with brentuximab vedotin will cost $13,500 per dose with seven to nine doses per trial treatment (124) .
Immunocytokine (ICK) can be considered another form of ADC with cytokine as a payload (131) . As a recombinant antibody-cytokine fusion protein instead of a chemical conjugate, ICK does not have the production issues of a typical ADC. Also, its cytokine is not packaged in the ICK as an inactive "pro-drug," and hence it exerts its biological activity once in circulation. Therefore, the concept of ICK relies on the specific targeting by the antibody moiety to bring the potent cytokine moiety to the tumor site to activate the tumor-infiltrating immune cells, resulting in the induction of a long-term protective immune response. Similar to ADC, the specificity of the antibody is of utmost importance to minimize its side effects. For treatment of infectious diseases, the cytokine can be chosen for its proinflammatory/antiinflammatory profile to suit the application. Furthermore, the cytokine can be further engineered to decrease systemic toxicity and increase the therapeutic index, as demonstrated by a low-toxicity IL-2 ICK (132).
Bispecific Antibodies
Combining mAbs with different mechanisms of action (MOAs) is another approach for improving the efficacy of mAbs, and is currently being explored in a number of clinical and preclinical programs. For example, different targets such as EGFR and insulin growth factor receptor can be combined to explore synergistic MOAs (133) or to suppress resistance mechanisms as described for EGFR and cMET (134) .
Monoclonal antibody combinations are challenging from a development and marketing perspective, since each single antibody as well as the combination will likely require regulatory testing and approval from authorities such as the FDA and European Medicines Evaluation Agency, leading to delays and a significant increase in development costs. In addition, the interdependency of efficacy and pharmacokinetics needs to be carefully studied. Bispecific antibody (bsAb) technologies appear to be an attractive alternative, because they offer a solution to combine synergistic MOAs in a single entity. In addition, bsAbs open new MOAs as demonstrated by Micromet's BiTE (135) , which physically links the effector cell to the target cell through a bridging mechanism that cannot be achieved by a combination of the two separate antibodies.
Although the bsAb concept provides a striking solution for the combination of different MOAs, production of these molecules turned out to be very challenging. Shortly after the invention of the mAb technology, Milstein and Cuello (136, 137) described the Quadroma technology for the production of bsAb which was essentially a hybrid of two hybridomas. Although scientifically very elegant, it became apparent that production in industrial scale was not feasible because of the complexity of the molecular species produced (138) . Other early approaches included chemical cross-linking (139, 140) , tandem fusions of ScFv or V domains (141, 142) , or their fusion to the C terminus of heavy chains. Up to now, only one bsAb, the anti-EpCAM x anti-CD3 catumaxomab (143) , has been approved in Europe for the treatment of malignant ascites. Catumaxomab is a rat/mouse chimeric IgG2a that is very immunogenic. Other bsAbs in advanced clinical development, such as the anti-CD19 x anti-CD3 blinatumomab (Micromet), are based on tandem fusions of scFvs and therefore do not display mAb effector functions or favorable pharmacokinetic properties such as a long serum half-life in humans.
A heterodimeric human Fc fusion retaining a long serum half-life and mAb-like effector functions is the ideal vehicle for engineering therapeutic bsAbs. Genentech's "knobs-into-holes" technology (144) offered a first technical solution by introducing different complementary mutations in the two CH3 domains that favor heterodimerization. Instead of designs based on steric considerations, heterodimerization could also be achieved by electrostatic steering (145) . Recently, Davis et al. (146) designed strand-exchange engineered domains (SEED), a novel bsAb platform based on the engineering of the CH3 domain. SEED is based on a rational design strategy that combines structurally related and conserved sequences of human IgG and IgA CH3 domains. By alternating sequences derived from both CH3 domains, two distinct SEED protein chains (designated AG and GA) were generated, creating asymmetric interfaces with modified β-sheet structures that preferentially heterodimerize. Because CH3 domains drive the heterodimerization of immunoglobulin heavy chains, AG and GA chains expressed in the context of antibody heavy chains can be utilized to produce monovalent and monospecific or bivalent and bispecific antibody-like molecules.
Since light chain pairing to the heavy chain is random during the assembly of a bispecific antibody, there is a need for a technology that can direct the specific pairing of the free light chain to its cognate heavy chain. The Crossmab approach uses immunoglobulin domain crossover (147) to get around this, while some technologies screen for a common light chain for the two different Fabs (148) , or use single variable domains to avoid the use of the light chain altogether (149) . One approach succeeded to provide a completely natural antibody with bispecific targeting by screening for a single Fv that can bind two different antigens. This "two-in-one" antibody uses an Fv variant of the antibody trastuzumab that interacts with both Her2 and vascular endothelial growth factor (150) . On the other hand, the dual variable domains-Ig approach covalently links the two VLs of different specificities, which then pair up with the two cognate VHs also similarly linked, thus creating the two variable domains of different specificities in tandem (151) .
In the development and design of the heterodimeric molecules, special care has to be taken so that the resulting bispecific molecule bears the same biological properties as the parental IgG molecule. This includes long serum half-life, ADCC and CDC, as well as excellent biophysical properties such as high protein homogeneity, protein A binding, and thermal stability. In addition, it is important to evaluate the manufacturability of this new molecule, including expression levels, ease of purification, thermal stability, and longterm storage potential. Only a molecule that has passed all of these tests would be ready for incorporation into the therapeutic pipeline.
